Phase 1 Renal Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride

Exclusion criteria

• ✕. potentially difficult airway (modified Mallampati score III-IV);
• ✕. hepatitis B surface antigen, hepatitis C antibody, HIV antibody or syphilis antibody positive;
• ✕. use of any drugs that inhibit or induce hepatic drug-metabolizing enzymes within 14 days before screening;
• ✕. a history of severe cardiovascular disease, including but not limited to organic heart disease, such as heart failure, myocardial infarction, angina pectoris, and malignant arrhythmia; Such as a history of torssion ventricular tachycardia, ventricular tachycardia, long QT syndrome or symptoms of long QT syndrome and family history (as indicated by genetic evidence or sudden death of a close relative at a young age due to cardiac causes);
• ✕. patients with severe infection, trauma, major surgery, or digestive system surgery within 1 month before screening that affect drug absorption;
• ✕. those with allergic constitution, such as those with a known history of allergic to two or more substances; Or who, as judged by the investigator, may be allergic to the trial drug or its excipients;
• ✕. binge drinking or regular drinking in the 6 months before screening, defined as drinking more than 14 units of alcohol per week (1 unit =360 mL of beer or 45 mL of 40% spirits or 150 mL of wine); Or with a positive alcohol breath test at baseline;
• ✕. smokers with an average of more than 5 cigarettes per day in the 3 months before screening or unable to quit smoking during the study;